HUMAN DISEASE MODELED by plpbp^ot101/+; plpbp^ot102/+

Human Disease	Conditions	Citations
early-onset vitamin B6-dependent epilepsy	standard conditions	Johnstone et al., 2019

GENE EXPRESSION
Gene expression in plpbp^ot101/+; plpbp^ot102/+

PHENOTYPE
Phenotype in plpbp^ot101/+; plpbp^ot102/+

Phenotype	Conditions	Figures
brain synaptic signaling ictal, abnormal	standard conditions	Fig. 4 from Johnstone et al., 2019
optic tectum synaptic signaling ictal, ameliorated	chemical treatment by environment: pyridoxine	Fig. 5 from Johnstone et al., 2019
whole organism dead, abnormal	standard conditions	Fig. 4 from Johnstone et al., 2019
whole organism dead, ameliorated	chemical treatment by environment: pyridoxine	Fig. 5 from Johnstone et al., 2019
whole organism dead, ameliorated	chemical treatment by environment: pyridoxal 5'-phosphate	Fig. 5 from Johnstone et al., 2019
whole organism decreased life span, abnormal	standard conditions	Fig. 4 from Johnstone et al., 2019
whole organism decreased life span, ameliorated	chemical treatment by environment: pyridoxine	Fig. 5 from Johnstone et al., 2019
whole organism decreased life span, ameliorated	chemical treatment by environment: pyridoxal 5'-phosphate	Fig. 5 from Johnstone et al., 2019
whole organism fosab expression increased amount, abnormal	standard conditions	Fig. 4 from Johnstone et al., 2019
whole organism 3-aminoisobutyric acid increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism alanine decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism alpha-aminobutyric acid decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism asparagine decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism beta-alanine increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism cystathionine increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism gamma-aminobutyric acid decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism glutamine decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism isoleucine increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism lysine decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism methionine increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism phenylalanine increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism proline decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism pyridoxal decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism pyridoxal 5'-phosphate decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism swimming behavior increased process quality, abnormal	standard conditions	Fig. 4 from Johnstone et al., 2019
whole organism swimming behavior increased process quality, ameliorated	chemical treatment by environment: pyridoxine	Fig. 5 from Johnstone et al., 2019
whole organism threonine decreased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism tryptophan increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019
whole organism tyrosine increased amount, abnormal	standard conditions	Fig. 6 from Johnstone et al., 2019